Molecular Cancer Research · 2020 · 84 citations · 43 references
Life SciencesMolecular BiologyOncologyMetabolismMetabolomicsMetastasisCancer MetabolismMetabolic PathwaysMetabolic ReprogrammingMetabolite ProfilingMetastatic Breast CancerMitochondrial MetabolismCancer Metabolic PhenotypingMetabolic Alterations In CancerMetabolic Pathway ProfilingMetastatic Breast Cancer BiologyMetastatic MetabolismPurine BiosynthesisSerine Hydroxymethyltransferase PathwaySerine Metabolism
Abstract Breast cancer is the most common cancer among American women and a major cause of mortality. To identify metabolic pathways as potential targets to treat metastatic breast cancer, we performed metabolomics profiling on the breast cancer cell line MDA-MB-231 and its tissue-tropic metastatic subclones. Here, we report that these subclones with increased metastatic potential display an altered metabolic profile compared with the parental population. In particular, the mitochondrial serine and one-carbon (1C) unit pathway is upregulated in metastatic subclones. Mechanistically, the mitochondrial serine and 1C unit pathway drives the faster proliferation of subclones through enhanced de novo purine biosynthesis. Inhibition of the first rate-limiting enzyme of the mitochondrial serine and 1C unit pathway, serine hydroxymethyltransferase (SHMT2), potently suppresses proliferation of metastatic subclones in culture and impairs growth of lung metastatic subclones at both primary and metastatic sites in mice. Some human breast cancers exhibit a significant association between the expression of genes in the mitochondrial serine and 1C unit pathway with disease outcome and higher expression of SHMT2 in metastatic tumor tissue compared with primary tumors. In addition to breast cancer, a few other cancer types, such as adrenocortical carcinoma and kidney chromophobe cell carcinoma, also display increased SHMT2 expression during disease progression. Together, these results suggest that mitochondrial serine and 1C unit metabolism plays an important role in promoting cancer progression, particularly in late-stage cancer. Implications: This study identifies mitochondrial serine and 1C unit metabolism as an important pathway during the progression of a subset of human breast cancers. See interview with Jiangbin Ye, PhD, co-recipient of the 2022 MCR Michael B. Kastan Award for Research Excellence: https://vimeo.com/720728048
43
In situ click chemistry generation of cyclooxygenase-2 inhibitors
Atul Bhardwaj, Jatinder Kaur, Melinda Wuest et al. · Nature Communications · 2017 · 7.6K citations · Full text
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis, Sohrab P. Shah, Suet‐Feung Chin et al. · Nature · 2012 · 6.4K citations · Full text
Life Sciences, Genetics, Oncology +14
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang et al. · Journal of Clinical Oncology · 2009 · 4.9K citations · Full text
Medicine, Bioinformatics, Oncology +16
Genes that mediate breast cancer metastasis to lung
Andy J. Minn, Gaorav P. Gupta, Peter M. Siegel et al. · Nature · 2005 · 3K citations · Full text